18th Mar 2020 17:03
(Alliance News) - Ergomed PLC on Wednesday said that it will provide clinical research services for the study of siltuximab, an interleukin-6 targeted monoclonal antibody, for the treatment of patients with Covid-19 who have developed serious respiratory complication.
The study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy, and supported by EUSA Pharma.
Shares in Ergomed closed 7.2% higher at 300.15 pence each in London on Wednesday.
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ERGO.L